Haptoglobin Phenotypes in Epilepsy (Technical Briefs) Haptoglobin Phenotypes in Epilepsy (Technical Briefs)

Haptoglobin Phenotypes in Epilepsy (Technical Briefs‪)‬

Clinical Chemistry 2004, June, 50, 6

    • $5.99
    • $5.99

Publisher Description

Seizures occur in ~5% of people, and recur in 20% of that 5% (1, 2). The etiologies of most seizures are unknown, and head trauma is implicated in only 5-10% of cases (3). Blood or blood components, specifically iron, may be etiologically important; intracranial injection of hemoglobin (4), lysed erythrocytes (5), iron-containing proteins (5), or iron salts (6) produced chronic focal spike activity in rodents and cats. Because microhemorrhagic events occur in the central nervous system of all people, inadequate clearance of iron-rich (7) hemoglobin might underlie development of some seizure disorders. Haptoglobin binds free hemoglobin and removes it from the circulation (8), thus preventing iron loss and kidney damage during hemolysis (9). Haptoglobin contains [beta]-(heavy; 40 kDa) and [alpha]-(light; [[alpha].sub.1] = 8.9 kDa and [[alpha].sub.2] = 16 kDa) chains. Humans are polymorphic for haptoglobin, with three major phenotypes: Hp 1-1, Hp 2-2, and the heterozygous Hp 2-1 (10). The [beta]-chains are identical in all, with variations dependent on different [alpha]-chains. Hp 1-1 expresses only the [alpha]1-chain and is the smallest form (86 kDa). Hp 2-1 and Hp 2-2 express [[alpha].sub.2]-chains, which can form polymers of 86-300 kDa (Hp 2-1) and up to 900 kDa (Hp 2-2) (10). Hp 1-1 is biologically the most effective in binding free hemoglobin and suppressing inflammatory responses associated with extracellular (free) hemoglobin (9). In contrast, Hp 2-2 is the least effective (11). The plasma concentrations of haptoglobin are highest in individuals with Hp 1-1 and lowest in those with Hp 2-2, with intermediate concentrations in Hp 2-1 individuals (9).

GENRE
Science & Nature
RELEASED
2004
June 1
LANGUAGE
EN
English
LENGTH
9
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
160
KB
Chemistry and Biochemistry of Oxygen Therapeutics Chemistry and Biochemistry of Oxygen Therapeutics
2011
Blood Substitutes Blood Substitutes
2005
Heme Biology Heme Biology
2020
Blood Substitutes, Present and Future Perspectives Blood Substitutes, Present and Future Perspectives
1999
Hemoglobin Variants and Hemoglobin [a.Sub.1C] Analysis: Problem Solved?(Editorial) Hemoglobin Variants and Hemoglobin [a.Sub.1C] Analysis: Problem Solved?(Editorial)
2003
Association of Serum Bilirubin Concentration with Risk of Coronary Artery Disease (Minireview) Association of Serum Bilirubin Concentration with Risk of Coronary Artery Disease (Minireview)
2000
Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial) Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial)
1997
Vitamin E and Coronary Heart Disease in Tunisians (Nutrition) (Clinical Report) Vitamin E and Coronary Heart Disease in Tunisians (Nutrition) (Clinical Report)
2000
Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome (Endocrinology and Metabolism) (Survey) Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome (Endocrinology and Metabolism) (Survey)
2007
Alanine Aminotransferase As an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease (Letters) (Letter to the Editor) Alanine Aminotransferase As an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease (Letters) (Letter to the Editor)
2007
T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis (Clinical Immunology) T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis (Clinical Immunology)
2007
Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers) Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers)
1998